Upload
joan-moody
View
220
Download
0
Embed Size (px)
Citation preview
Acute treatment of migraine
Dr Mark Weatherall
London Headache Centre
2010
The intangibles
Doctor-patient relationship Realistic expectations Education
Triggers
Hormonal Dietary Psychological Environmental Sleep Drugs
10 steps to success
Make the diagnosis Use the right drugs Use effective doses Treat early when the pains mild Treat associated symptoms
10 steps to success
Choose appropriate route of delivery Observe contraindications Use prior experience to select/reject drugs Avoid drugs with high potential for MOH Combine medications if necessary
Where to start?
paracetamol 1 gor, aspirin 900 mgor, ibuprofen 600-800 mg+/- domperidone 10-20 mg taken as soon as possible*ª
* i.e. as soon as the patient knows that this is a migraine
ª if there is aura, take at the start of the headache phase
Variations on a theme
if early nausea, you can use: soluble aspirin suppositories*:
diclofenac 75 mg domperidone 30 mg
*be French!
Headache response at 2 hr
Problems, problems…
Not effective dose? timing? route? combination?
Contraindications asthma, upper GI problems, renal impairment
Side effects GI, CNS
Codeine…?
… is NOT a treatment for headache the WHO analgesic ladder should NOT be
applied to headache management
Triptans
5-HT1B/1D receptor agonists seven different formulations options for route of delivery
oral tablets or melts nasal spray subcutaneous injection
taken as soon as possible*ª¹* i.e. as soon as the patient knows that this is a migraine
ª if there is aura, take at the start of the headache phase
¹ this is a race against the development of allodynia
Which triptan?
Headache response at 2 hr
Pain freedom at 2 hr
Problems, problems…
Ineffective dose? timing? route? switch?
Headache recurrence switch? combination with NSAID?
Contraindications HT, IHD
SE nausea, GI, CNS, ‘triptan chest’
Is the future ‘pants’?
CGRP antagonists two with data recently published proof-of-concept trial of intravenous BIBN4096BS
(now called olcagepant) was published in NEJM in 2004
phase II study of oral CGRP antagonist MK-0974 (now called telcagepant) presented at IHS 2007 and published in Neurology in 2008
multicentre phase III R-PT-PC-DB-T of oral telcagepant 150 or 300 mg vs zolmitriptan 5 mg and placebo published in The Lancet in last four weeks